JRD-SIK1/2i-4 is a potent, highly selective SIK1/2 inhibitor, modulates innate immune activation and suppress intestinal inflammation.
JRD-SIK1/2i-4 inhibits key intracellular proximal signaling events including reducing phosphorylation of the SIK substrate cAMP response element binding protein (CREB) regulated transcription coactivator 3 (CRTC3).
JRD-SIK1/2i-4 inhibits inflammatory cytokine production in primary human macrophages stimulated with TLR7/8-agonist R848.
JRD-SIK1/2i-4 suppresses IL-2 production by activated primary T cells, ameliorates disease in a murine colitis model.
